Artivion Completes Acquisition of Endospan Ltd.

Rhea-AI Summary

Artivion (NYSE:AORT) completed the acquisition of endovascular aortic arch specialist Endospan, developer of the NEXUS Aortic Arch System. The $135 million upfront net purchase price was funded using a previously drawn $150 million delayed draw term loan, with additional performance-based consideration possible.

The NEXUS branched endovascular stent graft system received FDA PMA approval in April 2026. Artivion has distributed NEXUS in EMEA since 2019 and, according to the company, this deal completes its three-part aortic arch portfolio alongside AMDS and ARCEVO LSA, adding a pipeline of next-generation arch technologies.

Positive

• Acquisition of Endospan completed, securing full ownership of NEXUS Aortic Arch System
• Funded $135 million upfront net purchase price with existing $150 million term loan
• NEXUS branched endovascular stent graft received FDA PMA approval in April 2026
• Artivion now combines NEXUS, AMDS, and ARCEVO LSA into a three-part aortic arch portfolio
• Acquisition adds a pipeline of next-generation aortic arch technologies in development

Negative

• Acquisition funding relies on a previously drawn $150 million delayed draw term loan
• Deal structure includes potential additional consideration tied to commercial performance, increasing total cost uncertainty

News Market Reaction – AORT

+4.35%

7 alerts

+4.35% Session close to close

$1.17B Market Cap

0.1x Rel. Volume

In the May 18 session, AORT gained 4.35%, reflecting a moderate positive market reaction. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement finalizes Artivion’s acquisition of Endospan, using a previously drawn $150 millio...

Analysis

This announcement finalizes Artivion’s acquisition of Endospan, using a previously drawn $150 million delayed draw term loan to fund the $135 million net upfront price. It consolidates control of the NEXUS Aortic Arch System, which received FDA PMA approval in April 2026 and has been distributed by Artivion in EMEA since 2019. Investors may track how this platform and its pipeline contribute to revenue and margins relative to earlier guidance changes and prior Endospan disclosures.

Key Figures

Delayed draw term loan: $150 million Upfront net purchase price: $135 million Additional consideration: Contingent on performance +5 more

8 metrics

Delayed draw term loan $150 million Previously drawn term loan used for Endospan acquisition funding

Upfront net purchase price $135 million Upfront net consideration for acquisition of Endospan

Additional consideration Contingent on performance Potential extra payments tied to Endospan commercial performance

FDA PMA approval date April 2026 U.S. PMA approval for NEXUS branched endovascular stent graft system

Exclusive distribution since 2019 Artivion as exclusive NEXUS distributor across EMEA

Current share price $23.06 Pre-news trading level on NYSE for AORT

52-week range $19.16–$48.25 Price sits well below the 52-week high

Market capitalization $1,113,099,016 Equity value before acquisition completion news

Historical Context

5 past events · Latest: May 07 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 07	Earnings and acquisition	Negative	-28.3%	Q1 2026 results, lowered 2026 guidance, and Endospan deal terms.
Apr 23	Earnings call setup	Neutral	+1.6%	Announcement of Q1 2026 release date and investor teleconference.
Apr 07	FDA approval	Positive	+5.3%	U.S. FDA approval of NEXUS Aortic Arch System enabling Endospan option.
Mar 03	Conference participation	Neutral	-0.3%	Participation in Oppenheimer MedTech & Services conference with webcast.
Feb 12	Earnings	Positive	-10.0%	Strong Q4 and 2025 results plus positive AMDS and NEXUS clinical data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows strong fundamental updates sometimes met with selling, as seen in the -28.26% reaction to Q1 2026 results and guidance alongside the Endospan deal.

Recent Company History

Over the last several months, Artivion has reported solid financial growth and advanced its aortic portfolio. Q4 2025 and Q1 2026 results highlighted double‑digit revenue gains and higher adjusted EBITDA, but the stock dropped ‑9.96% and ‑28.26% after those reports, when guidance was lowered and the Endospan acquisition terms were detailed. In April 2026, FDA approved the NEXUS Aortic Arch System, prompting a 5.29% gain. Today’s completion of the Endospan acquisition follows this sequence of FDA approval and option exercise previously disclosed.

Key Terms

endovascular, premarket approval application, pma, stent graft, +1 more

5 terms

endovascular medical

"a pioneer in the endovascular repair of aortic arch disease"

Endovascular describes medical procedures performed inside blood vessels using thin tubes, wires, and implantable devices guided by imaging—like repairing a broken pipe from the inside rather than opening the wall. It matters to investors because these less-invasive techniques can shorten hospital stays, lower complication rates and create demand for specialized devices and imaging equipment, so changes in adoption, regulation or reimbursement can materially affect healthcare company revenues and margins.

premarket approval application regulatory

"The U.S. Food and Drug Administration (FDA) approved the premarket approval application (PMA)"

A premarket approval application is a formal, data-packed request submitted to regulators to get permission to sell a high-risk medical device. It is like asking for a driver’s license for a complex product: the company must show clinical trial results, safety testing and manufacturing controls to prove the device works and won’t harm people. Investors watch these filings because approval unlocks revenue and sharply reduces the regulatory risk that can halt a product’s commercial launch.

pma regulatory

"FDA approved the premarket approval application (PMA) for the NEXUS branched endovascular stent graft system"

PMA stands for Premarket Approval, the U.S. Food and Drug Administration’s highest-level review for high-risk medical devices. It’s a thorough evaluation to confirm a device is safe and effective before it can be sold, like a final safety inspection and license to operate. Investors care because receiving PMA can open a significant revenue stream, while delays or rejection can postpone sales and reduce a company’s value.

stent graft medical

"for the NEXUS branched endovascular stent graft system in April 2026"

A stent graft is a tube-shaped medical device made of a metal scaffold covered with fabric that is placed inside a blood vessel to reinforce weakened walls and seal leaks, much like inserting a strong inner sleeve to patch a worn pipe. Investors monitor stent grafts because their regulatory approvals, clinical success, manufacturing capacity and reimbursement determine sales potential and legal or safety risks that can significantly affect a medical device maker’s revenue and valuation.

aortic arch medical

"developer of the NEXUS® Aortic Arch System"

The aortic arch is the curved top portion of the body's main artery that carries blood from the heart and branches off to supply the brain, arms and upper body — think of it as a highway interchange where major roads split from the main route. It matters to investors because diseases, injuries or surgeries involving the aortic arch often require specialized drugs, devices or procedures that drive clinical trials, regulatory reviews, revenue opportunities and potential liability for companies in healthcare and medical technology.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ATLANTA, May 18, 2026 Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed the acquisition of its long-standing partner Endospan Ltd. ("Endospan"), a pioneer in the endovascular repair of aortic arch disease  and developer of the NEXUS® Aortic Arch System. Artivion utilized its previously drawn $150 million delayed draw term loan to fund the $135 million upfront net purchase price for Endospan. The transaction also includes potential additional consideration contingent on commercial performance.

The U.S. Food and Drug Administration (FDA) approved the premarket approval application (PMA) for the NEXUS branched endovascular stent graft system in April 2026. Artivion has acted as the exclusive distributor of the NEXUS System across EMEA since 2019.

"Our acquisition of Endospan and its NEXUS system completes our market-leading, three-pronged aortic arch portfolio. This technology, alongside AMDS and ARCEVO LSA, positions us at the forefront of this segment as the only company globally with a complete portfolio of aortic arch solutions," said Pat Mackin, Chairman, President, and Chief Executive Officer. "Further, NEXUS is a platform technology, not just a single product. With this acquisition, we are also adding a robust pipeline of next-generation arch technologies currently in development that we expect will further expand and strengthen our leadership position in the aortic arch market over time."

About Artivion, Inc.

Headquartered in suburban Atlanta, Georgia, Artivion, Inc., is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.Artivion.com.

About Endospan Ltd.

Privately held Endospan, headquartered in Herzliya (Tel Aviv), Israel, is a pioneer in the endovascular repair of aortic arch disease including aneurysms and dissections. Endospan has received CE-Mark to commercialize in Europe the NEXUS Stent Graft System, the first endovascular off-the-shelf system to treat Aortic Arch Disease which affects a greatly underserved group of patients diagnosed with a dilative lesion in, or near, the aortic arch. While minimally invasive endovascular repair has been the standard of care for Abdominal Aortic Aneurysm (AAA), Aortic Arch Disease patients with aneurysms or dissections have not been as fortunate and have had little choice but to undergo open-chest surgery with its invasiveness and risks, lengthy hospitalization periods, and prolonged recuperation. For additional information about Endospan, visit their website, www.endospan.com.

Contacts:
Artivion	Gilmartin Group LLC
Lance A. Berry	Brian Johnston
Executive Vice President,	Phone: 332-895-3222
Chief Operating Officer &	investors@artivion.com
Chief Financial Officer
Phone: 770-419-3355

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/artivion-completes-acquisition-of-endospan-ltd-302774254.html

SOURCE Artivion, Inc.

FAQ

What did Artivion (NYSE:AORT) announce about its acquisition of Endospan in May 2026?

Artivion announced it has completed the acquisition of Endospan, its long-standing partner in endovascular aortic arch repair. According to Artivion, the deal secures the NEXUS Aortic Arch System and adds a pipeline of next-generation aortic arch technologies to its portfolio.

How much did Artivion pay upfront to acquire Endospan and how was it funded?

Artivion funded a $135 million upfront net purchase price for Endospan using a previously drawn $150 million delayed draw term loan. According to Artivion, the transaction also includes potential additional consideration contingent on Endospan’s commercial performance over time.

What is the NEXUS Aortic Arch System and what recent FDA approval did it receive?

The NEXUS Aortic Arch System is a branched endovascular stent graft for aortic arch disease. According to Artivion, the U.S. FDA approved the premarket approval application (PMA) for the NEXUS branched endovascular stent graft system in April 2026, enabling broader commercialization.

How does the Endospan acquisition affect Artivion’s aortic arch product portfolio (AORT)?

The acquisition completes Artivion’s three-pronged aortic arch portfolio by adding NEXUS alongside AMDS and ARCEVO LSA. According to Artivion, this combination creates a comprehensive suite of aortic arch solutions and brings in a robust pipeline of next-generation arch technologies.

What are the potential future payments in Artivion’s acquisition of Endospan?

Beyond the $135 million upfront net purchase price, the transaction includes potential additional consideration. According to Artivion, these extra payments are contingent on Endospan’s commercial performance, meaning the ultimate acquisition cost could rise depending on future sales results.

How long has Artivion been involved with Endospan’s NEXUS System before the acquisition?

Artivion has acted as the exclusive distributor of the NEXUS System across EMEA since 2019. According to Artivion, the completed acquisition builds on this long-standing partnership and transitions the relationship from distribution-only to full ownership of the NEXUS technology platform.